Entellus Medical, Inc. (NASDAQ:ENTL) Director Brian E. Farley sold 40,000 shares of Entellus Medical stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $19.78, for a total value of $791,200.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Brian E. Farley also recently made the following trade(s):

  • On Tuesday, October 3rd, Brian E. Farley sold 6,028 shares of Entellus Medical stock. The shares were sold at an average price of $19.17, for a total value of $115,556.76.
  • On Monday, October 2nd, Brian E. Farley sold 3,972 shares of Entellus Medical stock. The shares were sold at an average price of $19.10, for a total value of $75,865.20.

Entellus Medical, Inc. (NASDAQ ENTL) opened at 20.30 on Friday. Entellus Medical, Inc. has a one year low of $12.31 and a one year high of $21.93. The firm’s market capitalization is $515.03 million. The stock has a 50 day moving average price of $18.04 and a 200 day moving average price of $18.04.

Entellus Medical (NASDAQ:ENTL) last issued its earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). Entellus Medical had a negative net margin of 41.11% and a negative return on equity of 60.34%. The company had revenue of $22.10 million during the quarter, compared to analyst estimates of $21.87 million. During the same quarter in the prior year, the business earned ($0.27) EPS. The business’s quarterly revenue was up 18.0% on a year-over-year basis. On average, equities analysts predict that Entellus Medical, Inc. will post ($1.61) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.watchlistnews.com/insider-selling-entellus-medical-inc-entl-director-sells-791200-00-in-stock/1614520.html.

A number of institutional investors have recently modified their holdings of ENTL. Bank of America Corp DE boosted its position in Entellus Medical by 53.8% in the first quarter. Bank of America Corp DE now owns 7,418 shares of the medical technology company’s stock valued at $102,000 after buying an additional 2,594 shares in the last quarter. Nationwide Fund Advisors boosted its position in Entellus Medical by 61.7% in the second quarter. Nationwide Fund Advisors now owns 6,903 shares of the medical technology company’s stock valued at $114,000 after buying an additional 2,635 shares in the last quarter. First Mercantile Trust Co. boosted its position in Entellus Medical by 45.3% in the second quarter. First Mercantile Trust Co. now owns 8,206 shares of the medical technology company’s stock valued at $136,000 after buying an additional 2,557 shares in the last quarter. Parametric Portfolio Associates LLC boosted its position in Entellus Medical by 5.6% in the first quarter. Parametric Portfolio Associates LLC now owns 10,888 shares of the medical technology company’s stock valued at $150,000 after buying an additional 573 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in Entellus Medical by 61.7% in the second quarter. The Manufacturers Life Insurance Company now owns 11,881 shares of the medical technology company’s stock valued at $196,000 after buying an additional 4,533 shares in the last quarter. Hedge funds and other institutional investors own 70.24% of the company’s stock.

A number of equities research analysts have weighed in on ENTL shares. Piper Jaffray Companies reaffirmed a “buy” rating and set a $21.00 price objective on shares of Entellus Medical in a report on Tuesday, August 22nd. BidaskClub raised Entellus Medical from a “hold” rating to a “buy” rating in a report on Saturday, August 19th. Finally, Zacks Investment Research downgraded Entellus Medical from a “hold” rating to a “sell” rating in a report on Tuesday. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $21.83.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Insider Buying and Selling by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.